# Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

> **NCT06318260** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Steen Hvitfeldt Poulsen** · enrollment: 35 (estimated)

## Conditions studied

- ATTR Amyloidosis Wild Type

## Interventions

- **DRUG:** Dobutrex

## Key facts

- **NCT ID:** NCT06318260
- **Lead sponsor:** Steen Hvitfeldt Poulsen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-08
- **Primary completion:** 2025-09
- **Final completion:** 2026-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318260, "Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06318260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*